OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
‘PARP’ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors
Pooja Dhileepkumar Rao, Himanshu Sankrityayan, Anjali Srivastava, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 7, pp. 1253-1261
Closed Access | Times Cited: 14
Pooja Dhileepkumar Rao, Himanshu Sankrityayan, Anjali Srivastava, et al.
Drug Discovery Today (2020) Vol. 25, Iss. 7, pp. 1253-1261
Closed Access | Times Cited: 14
Showing 14 citing articles:
Poly(ADP-ribose) polymerase inhibition: past, present and future
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 407
Nicola J. Curtin, Csaba Szabó
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 10, pp. 711-736
Closed Access | Times Cited: 407
TWEAK/Fn14 axis is an important player in fibrosis
Yitian Zhang, Weihui Zeng, Yumin Xia
Journal of Cellular Physiology (2020) Vol. 236, Iss. 5, pp. 3304-3316
Closed Access | Times Cited: 34
Yitian Zhang, Weihui Zeng, Yumin Xia
Journal of Cellular Physiology (2020) Vol. 236, Iss. 5, pp. 3304-3316
Closed Access | Times Cited: 34
Established and Emerging Cancer Therapies and Cardiovascular System: Focus on Hypertension—Mechanisms and Mitigation
Lloyd Butel-Simoes, Tatt Jhong Haw, Trent Williams, et al.
Hypertension (2023) Vol. 80, Iss. 4, pp. 685-710
Open Access | Times Cited: 11
Lloyd Butel-Simoes, Tatt Jhong Haw, Trent Williams, et al.
Hypertension (2023) Vol. 80, Iss. 4, pp. 685-710
Open Access | Times Cited: 11
Dihydrokaempferol attenuates CCl4-induced hepatic fibrosis by inhibiting PARP-1 to affect multiple downstream pathways and cytokines
Hancheng Huang, Shuchun Wei, Xiaohan Wu, et al.
Toxicology and Applied Pharmacology (2023) Vol. 464, pp. 116438-116438
Open Access | Times Cited: 10
Hancheng Huang, Shuchun Wei, Xiaohan Wu, et al.
Toxicology and Applied Pharmacology (2023) Vol. 464, pp. 116438-116438
Open Access | Times Cited: 10
Perioperative Drug Management of Systemic Therapies in Breast Cancer: A Literature Review and Treatment Recommendations
Mariem Galuia, Julia Fedorova, Wassim Mchayleh, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 154-154
Open Access
Mariem Galuia, Julia Fedorova, Wassim Mchayleh, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 154-154
Open Access
Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function
Jiajia Li, Qingchao Li, Lingyi Zhang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 157, pp. 114028-114028
Open Access | Times Cited: 16
Jiajia Li, Qingchao Li, Lingyi Zhang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 157, pp. 114028-114028
Open Access | Times Cited: 16
Hyperoside attenuates carbon tetrachloride-induced hepatic fibrosis via the poly(ADP-ribose)polymerase-1-high mobility group protein 1 pathway
Huihong Zeng, Mei Ma, Yulan Wang, et al.
European Journal of Pharmacology (2023) Vol. 960, pp. 176178-176178
Open Access | Times Cited: 8
Huihong Zeng, Mei Ma, Yulan Wang, et al.
European Journal of Pharmacology (2023) Vol. 960, pp. 176178-176178
Open Access | Times Cited: 8
Cell death induced by acute renal injury: a perspective on the contributions of accidental and programmed cell death
Mi Ra Noh, Babu J. Padanilam
AJP Renal Physiology (2024) Vol. 327, Iss. 1, pp. F4-F20
Closed Access | Times Cited: 3
Mi Ra Noh, Babu J. Padanilam
AJP Renal Physiology (2024) Vol. 327, Iss. 1, pp. F4-F20
Closed Access | Times Cited: 3
ADP‐ribosylation in evasion, promotion and exacerbation of immune responses
Maria Manuela Rosado, Claudio Pioli
Immunology (2021) Vol. 164, Iss. 1, pp. 15-30
Open Access | Times Cited: 14
Maria Manuela Rosado, Claudio Pioli
Immunology (2021) Vol. 164, Iss. 1, pp. 15-30
Open Access | Times Cited: 14
Roles of DNA damage repair and precise targeted therapy in renal cancer (Review)
Yongchang Lai, Zhibiao Li, Zechao Lu, et al.
Oncology Reports (2022) Vol. 48, Iss. 6
Open Access | Times Cited: 10
Yongchang Lai, Zhibiao Li, Zechao Lu, et al.
Oncology Reports (2022) Vol. 48, Iss. 6
Open Access | Times Cited: 10
Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma
Sharon H. Choi, Yu‐Wei Chen, Justine Panian, et al.
The Oncologist (2024)
Open Access | Times Cited: 1
Sharon H. Choi, Yu‐Wei Chen, Justine Panian, et al.
The Oncologist (2024)
Open Access | Times Cited: 1
Poly(ADP-Ribosyl) Code Functions
Natalya Maluchenko, Darya O. Koshkina, Alexey V. Feofanov, et al.
Acta Naturae (2021) Vol. 13, Iss. 2, pp. 58-69
Open Access | Times Cited: 8
Natalya Maluchenko, Darya O. Koshkina, Alexey V. Feofanov, et al.
Acta Naturae (2021) Vol. 13, Iss. 2, pp. 58-69
Open Access | Times Cited: 8
Predictive investigation of idiopathic pulmonary fibrosis subtypes based on cellular senescence-related genes for disease treatment and management
Changqing Yang, Ziqi Han, Wenyu Zhan, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 3
Changqing Yang, Ziqi Han, Wenyu Zhan, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 3
Dexmedetomidine suppresses bupivacaine-induced parthanatos in human SH-SY5Y cells via the miR-7-5p/PARP1 axis-mediated ROS
Ting Zheng, Chunying Zheng, Fei Gao, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2020) Vol. 394, Iss. 4, pp. 783-796
Closed Access | Times Cited: 6
Ting Zheng, Chunying Zheng, Fei Gao, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2020) Vol. 394, Iss. 4, pp. 783-796
Closed Access | Times Cited: 6
